News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
31,402 Results
Type
Article (1514)
Company Profile (3)
Press Release (29885)
Section
Business (14586)
Career Advice (84)
Deals (1790)
Drug Development (3171)
Employer Resources (1)
FDA (568)
Job Trends (636)
News (19259)
Policy (857)
Tag
Academia (43)
Accelerated approval (1)
Allergies (3)
Alliances (1089)
ALS (3)
Alzheimer's disease (26)
Antibody-drug conjugate (ADC) (3)
Approvals (573)
Artificial intelligence (5)
Autoimmune disease (1)
Automation (1)
Bankruptcy (6)
Best Places to Work (553)
Biosimilars (3)
Biotechnology (2)
Bladder cancer (5)
Brain cancer (2)
Breast cancer (28)
Cancer (98)
Cardiovascular disease (6)
Career advice (82)
Cell therapy (7)
Clinical research (2699)
Collaboration (10)
Company closure (1)
Compensation (6)
COVID-19 (56)
CRISPR (1)
C-suite (2)
Cystic fibrosis (8)
Data (126)
Depression (1)
Diabetes (9)
Diagnostics (264)
Digital health (3)
Drug discovery (3)
Duchenne muscular dystrophy (3)
Earnings (13159)
Employer resources (1)
Events (2148)
Executive appointments (5)
FDA (657)
Frontotemporal dementia (1)
Funding (12)
Gene editing (1)
Generative AI (1)
Gene therapy (9)
GLP-1 (19)
Government (75)
Guidances (47)
Healthcare (743)
IgA nephropathy (3)
Immunology and inflammation (3)
Indications (2)
Infectious disease (61)
Inflammatory bowel disease (7)
Intellectual property (3)
Interviews (13)
IPO (1355)
Job creations (120)
Job search strategy (69)
Kidney cancer (2)
Layoffs (8)
Legal (112)
Lung cancer (17)
Lymphoma (4)
Management (1)
Manufacturing (3)
MASH (6)
Medical device (692)
Medtech (692)
Mergers & acquisitions (453)
Metabolic disorders (24)
Multiple sclerosis (10)
NASH (1)
Neurodegenerative disease (2)
Neuropsychiatric disorders (1)
Neuroscience (46)
NextGen: Class of 2025 (140)
Non-profit (56)
Obesity (9)
Opinion (3)
Ovarian cancer (3)
Pain (2)
Pancreatic cancer (1)
Parkinson's disease (2)
Patents (7)
Patient recruitment (2)
Peanut (1)
People (855)
Pharmaceutical (2)
Phase I (655)
Phase II (1070)
Phase III (1019)
Pipeline (264)
Postmarket research (191)
Preclinical (381)
Press Release (1)
Prostate cancer (3)
Radiopharmaceuticals (9)
Rare diseases (19)
Real estate (155)
Recruiting (1)
Regulatory (732)
Reports (4)
Research institute (41)
Resumes & cover letters (2)
RSV (4)
Schizophrenia (3)
Sickle cell disease (4)
Special edition (1)
Spinal muscular atrophy (5)
Sponsored (1)
Startups (59)
Stomach cancer (1)
Vaccines (10)
Venture capitalists (1)
Weight loss (4)
Women's health (1)
Date
Today (6)
Last 7 days (104)
Last 30 days (196)
Last 365 days (1745)
2025 (679)
2024 (1940)
2023 (2174)
2022 (3185)
2021 (3778)
2020 (2912)
2019 (1382)
2018 (1071)
2017 (867)
2016 (569)
2015 (779)
2014 (526)
2013 (313)
2012 (403)
2011 (494)
2010 (459)
Location
Africa (23)
Alabama (1)
Arizona (8)
Arkansas (1)
Asia (1642)
Australia (239)
California (338)
Canada (87)
China (25)
Colorado (16)
Connecticut (20)
Delaware (15)
Europe (3727)
Florida (44)
Georgia (14)
Idaho (1)
Illinois (26)
India (1)
Indiana (25)
Japan (9)
Louisiana (4)
Maine (11)
Maryland (46)
Massachusetts (257)
Michigan (26)
Minnesota (18)
Missouri (5)
Montana (1)
Nevada (1)
New Hampshire (6)
New Jersey (158)
New York (74)
North Carolina (39)
Northern California (152)
Ohio (14)
Pennsylvania (90)
South America (36)
Southern California (150)
Tennessee (3)
Texas (38)
United States (1343)
Utah (21)
Virginia (4)
Washington D.C. (1)
Washington State (38)
Wisconsin (1)
31,402 Results for "109".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SOTIO Reports Promising Preclinical Data on Antibody-Drug Conjugates SOT109 and SOT106, Underscoring Best-in-Class Potential for Solid Tumor Treatments
April 29, 2025
·
4 min read
Press Releases
SOTIO to Present Preclinical Data on Lead Antibody-Drug Conjugates, SOT106 and SOT109, at 2025 AACR Annual Meeting
March 26, 2025
·
2 min read
Press Releases
Apnimed to Host Virtual Investor Event Highlighting the Potential for AD109 as a Novel Pharmacotherapy for Obstructive Sleep Apnea on April 11, 2025
March 26, 2025
·
6 min read
Press Releases
SOTIO Unveils Promising Preclinical Data on SOT109, a Next-Gen ADC Targeting Cadherin-17 (CDH17) for Colorectal Cancer
March 4, 2025
·
3 min read
Press Releases
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
January 21, 2025
·
7 min read
Press Releases
Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment
January 9, 2025
·
4 min read
Press Releases
Orion Research Foundation grants EUR 1,109,000 for research in 2025
November 22, 2024
·
4 min read
Press Releases
SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target
January 9, 2025
·
4 min read
Drug Development
Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
Apnimed announced the early completion of enrollment in its LunAIRo Phase 3 study designed to examine the efficacy and safety of its lead candidate AD109 compared to placebo at six months and one year.
May 9, 2024
·
7 min read
Drug Development
Sionna Therapeutics Announces Phase 1 Initiation for SION-109 in Cystic Fibrosis
Sionna Therapeutics today announced that the first healthy subject has been dosed in a Phase 1 clinical trial of SION-109 following clearance of its Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA).
January 24, 2024
·
2 min read
1 of 3,141
Next
